Drug Profile
Pneumococcal vaccine - GlaxoSmithKline
Alternative Names: 2830929A; 2830930A; GSK2830929A; GSK2830930ALatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pneumococcal infections
Most Recent Events
- 17 Mar 2016 Phase-II development is ongoing in European Union
- 01 Jan 2014 GlaxoSmithKline completes a phase II trial in Pneumococcal infections (in infants, prevention) in Belgium, Czech Republic, Germany, Poland, Spain (NCT01616459)
- 02 May 2012 Phase-II clinical trials in Pneumococcal infections (in infants, prevention) in Belgium, Czech Republic, Germany, Poland and Spain (IM)